Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C3Mab-2: An Anti-Mouse CCR3 Monoclonal Antibody for Immunocytochemistry.
Saito M, Harigae Y, Li G, Asano T, Tanaka T, Suzuki H, Kaneko MK, Kato Y. Saito M, et al. Among authors: li g. Monoclon Antib Immunodiagn Immunother. 2022 Feb;41(1):45-49. doi: 10.1089/mab.2021.0050. Monoclon Antib Immunodiagn Immunother. 2022. PMID: 35225661
Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody.
Goto N, Suzuki H, Ohishi T, Harakawa A, Li G, Saito M, Takei J, Tanaka T, Asano T, Sano M, Kawada M, Kaneko MK, Kato Y. Goto N, et al. Among authors: li g. Monoclon Antib Immunodiagn Immunother. 2022 Apr;41(2):67-73. doi: 10.1089/mab.2021.0059. Epub 2022 Apr 4. Monoclon Antib Immunodiagn Immunother. 2022. PMID: 35377239
C9Mab-1: An Anti-Mouse CCR9 Monoclonal Antibody for Immunocytochemistry.
Saito M, Suzuki H, Harigae Y, Li G, Tanaka T, Asano T, Kaneko MK, Kato Y. Saito M, et al. Among authors: li g. Monoclon Antib Immunodiagn Immunother. 2022 Apr;41(2):120-124. doi: 10.1089/mab.2021.0052. Monoclon Antib Immunodiagn Immunother. 2022. PMID: 35471047
46,121 results
You have reached the last available page of results. Please see the User Guide for more information.